search
Back to results

Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot

Primary Purpose

Post-traumatic Stress Disorder

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Translingual neurostimulation
Sponsored by
HealthTech Connex Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-traumatic Stress Disorder

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female, at least 19 years of age or older
  2. A score of 33 or more on the Posttraumatic Stress Disorder Checklist (PCL-5)
  3. PTSD symptom duration of ≥ 12 months
  4. Stable dose of any medications for the last three months, with no changes anticipated for the duration of the study
  5. Adequate support at home (e.g., family member or caregiver) to ensure assistance in seeking access to help if needed
  6. Able to understand the informed consent form, study procedures and willing to participate in study
  7. Currently has a primary care provider

Exclusion Criteria:

  1. History of substance dependence or abuse (within the last 3 months)
  2. Unstable psychosocial settings (homelessness, lack of support at home)
  3. Moderate to high risk of suicidal ideation or behaviour as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
  4. Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder
  5. Use of medications for PTSD within the last 6 weeks
  6. History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke)
  7. Detection of mild cognitive impairment (mini-ACE score of ≤ 25)
  8. Diagnosed epilepsy or history of seizures
  9. Not proficient in English
  10. Recent (within last 2 years) acquired brain injury
  11. Exposed to an investigational drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study
  12. If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding
  13. Contraindicated for the NeuroCatchTM Platform, including:

    13.1. Requires the use of hearing aids or a cochlear implant 13.2. Diagnosed with tinnitus that is currently active 13.3. Has temporary damage to earing (e.g. punctured ear drum) 13.4. Unable to detect a 740Hz tone played at 85dB in both ears. 13.5. Implanted pacemaker or implanted electrical stimulators 13.6. Metal or plastic implants in the skull, excluding dental/facial implants 13.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 13.8. Previous exposure to the NeuroCatch™ Platform audio sequences in the last 3 months

  14. Contraindicated for PoNSTM use, including:

14.1. Current disease or sensitivity of the oral cavity 14.2. History of oral cancer 14.3. Oral surgery within three months of screening 14.4. Oral cavity piercings that could interfere with PoNSTM use 14.5. Sensitivity to Nickel, Copper, or Gold 14.6. Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks 14.7. History of penetrating brain injuries 14.8. History of neurodegenerative diseases 14.9. Chronic infectious disease 14.10. Unmanaged hypertension 14.11. Diabetes 14.12. History of seizures

Sites / Locations

  • Centre for Neurology Studies

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

TLNS

Control

Arm Description

Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions

No TLNS

Outcomes

Primary Outcome Measures

Proportion of participants screened who are eligible
Reach (RE-AIM framework)
Clinician-rated symptom severity as measured by CAPS
Effectiveness (RE-AIM framework)
Participant rated symptom severity as measured by the PCL-5
Effectiveness (RE-AIM framework)
Proportion of therapy visits completed
Adoption (RE-AIM framework)
Ease of protocol administration
Adoption (RE-AIM framework); 5-point Likert scale for participants and therapists
Qualitative report of barriers and facilitators
Implementation (RE-AIM framework)

Secondary Outcome Measures

Electroencephalography (EEG)
Using the NeuroCatchTM Platform - EEG amplitudes
Electroencephalography (EEG)
Using the NeuroCatchTM Platform - EEG latencies
Generalized Anxiety Disorder 7-item (GAD-7)
Anxiety symptom severity self-report measure
Patient Health Questionnaire (PHQ-9)
Depression symptom severity self-report measure
Brief Inventory of Psychosocial Functioning (B-IPF)
PTSD-related functional impairment in the prior 30 days
Meaning in Life Questionnaire (MLQ)
Assesses two dimensions of meaning in life using 10 items rated on a seven-point scale
Time from inciting event
Time since traumatic event (years)

Full Information

First Posted
October 15, 2021
Last Updated
August 1, 2023
Sponsor
HealthTech Connex Inc.
Collaborators
Centre for Neurology Studies
search

1. Study Identification

Unique Protocol Identification Number
NCT05112003
Brief Title
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
Official Title
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
September 22, 2021 (Actual)
Primary Completion Date
April 12, 2023 (Actual)
Study Completion Date
July 6, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HealthTech Connex Inc.
Collaborators
Centre for Neurology Studies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A growing body of evidence suggests that translingual neurostimulation (TLNS) plays a role in modulating neuroplastic changes in the brain, which has far-reaching implications for its ability to facilitate other therapeutic interventions such as cognitive processing therapy (CPT) for post-traumatic stress disorder (PTSD). The present study aims to assess the feasibility of combining TLNS with CPT in individuals with PTSD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-traumatic Stress Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TLNS
Arm Type
Experimental
Arm Description
Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
Arm Title
Control
Arm Type
No Intervention
Arm Description
No TLNS
Intervention Type
Device
Intervention Name(s)
Translingual neurostimulation
Intervention Description
The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
Primary Outcome Measure Information:
Title
Proportion of participants screened who are eligible
Description
Reach (RE-AIM framework)
Time Frame
Baseline to week 6
Title
Clinician-rated symptom severity as measured by CAPS
Description
Effectiveness (RE-AIM framework)
Time Frame
Change from baseline to week 6
Title
Participant rated symptom severity as measured by the PCL-5
Description
Effectiveness (RE-AIM framework)
Time Frame
Change from baseline to week 6
Title
Proportion of therapy visits completed
Description
Adoption (RE-AIM framework)
Time Frame
Baseline to Week 6
Title
Ease of protocol administration
Description
Adoption (RE-AIM framework); 5-point Likert scale for participants and therapists
Time Frame
Baseline to week 6
Title
Qualitative report of barriers and facilitators
Description
Implementation (RE-AIM framework)
Time Frame
Baseline to week 6
Secondary Outcome Measure Information:
Title
Electroencephalography (EEG)
Description
Using the NeuroCatchTM Platform - EEG amplitudes
Time Frame
Change from baseline to week 6
Title
Electroencephalography (EEG)
Description
Using the NeuroCatchTM Platform - EEG latencies
Time Frame
Change from baseline to week 6
Title
Generalized Anxiety Disorder 7-item (GAD-7)
Description
Anxiety symptom severity self-report measure
Time Frame
Change from baseline to week 6
Title
Patient Health Questionnaire (PHQ-9)
Description
Depression symptom severity self-report measure
Time Frame
Change from baseline to week 6
Title
Brief Inventory of Psychosocial Functioning (B-IPF)
Description
PTSD-related functional impairment in the prior 30 days
Time Frame
Change from baseline to week 6
Title
Meaning in Life Questionnaire (MLQ)
Description
Assesses two dimensions of meaning in life using 10 items rated on a seven-point scale
Time Frame
Change from baseline to week 6
Title
Time from inciting event
Description
Time since traumatic event (years)
Time Frame
Baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, at least 19 years of age or older A score of 33 or more on the Posttraumatic Stress Disorder Checklist (PCL-5) PTSD symptom duration of ≥ 12 months Stable dose of any medications for the last three months, with no changes anticipated for the duration of the study Adequate support at home (e.g., family member or caregiver) to ensure assistance in seeking access to help if needed Able to understand the informed consent form, study procedures and willing to participate in study Currently has a primary care provider Exclusion Criteria: History of substance dependence or abuse (within the last 3 months) Unstable psychosocial settings (homelessness, lack of support at home) Moderate to high risk of suicidal ideation or behaviour as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder Use of medications for PTSD within the last 6 weeks History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke) Detection of mild cognitive impairment (mini-ACE score of ≤ 25) Diagnosed epilepsy or history of seizures Not proficient in English Recent (within last 2 years) acquired brain injury Exposed to an investigational drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding Contraindicated for the NeuroCatchTM Platform, including: 13.1. Requires the use of hearing aids or a cochlear implant 13.2. Diagnosed with tinnitus that is currently active 13.3. Has temporary damage to earing (e.g. punctured ear drum) 13.4. Unable to detect a 740Hz tone played at 85dB in both ears. 13.5. Implanted pacemaker or implanted electrical stimulators 13.6. Metal or plastic implants in the skull, excluding dental/facial implants 13.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 13.8. Previous exposure to the NeuroCatch™ Platform audio sequences in the last 3 months Contraindicated for PoNSTM use, including: 14.1. Current disease or sensitivity of the oral cavity 14.2. History of oral cancer 14.3. Oral surgery within three months of screening 14.4. Oral cavity piercings that could interfere with PoNSTM use 14.5. Sensitivity to Nickel, Copper, or Gold 14.6. Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks 14.7. History of penetrating brain injuries 14.8. History of neurodegenerative diseases 14.9. Chronic infectious disease 14.10. Unmanaged hypertension 14.11. Diabetes 14.12. History of seizures
Facility Information:
Facility Name
Centre for Neurology Studies
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V 0C6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
https://centreforneurologystudies.com/neurostimulation-therapy-for-post-traumatic-stress-disorder/
Description
Study sign-up page

Learn more about this trial

Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot

We'll reach out to this number within 24 hrs